LEGN, 5/20-5/23, -9.5% LOSS
Legend Biotech (LEGN) reported a loss of $0.16 per share on revenue of $93.99 million for the first quarter ended March 2024. The consensus estimate was a loss of $0.29 per share on revenue of $152.60 million. The company reported in-line with expectations while revenue grew 158.67% on a year-over-year basis.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.